Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia.
Summers
Shaun A
SA
Renal Medicine, Southend General Hospital, Westcliff-on-Sea, Essex, UK. shaunsummers@hotmail.com
Matijevic
Ante
A
Almond
Mike K
MK
D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000276:immunology; D016572:Cyclosporine / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004351:Drug Resistance; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000276:immunology; D006435:Renal Dialysis; D017701:Reticulocyte Count; D019233:Retreatment
D000906:Antibodies; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D016572:Cyclosporine